Transcatheter Aortic Valve Implantation: Addressing the Subsequent Risk of Permanent Pacemaker Implantation.
Philipp LautenLisa C Costello-BoerrigterBjörn GoebelDavid Gonzalez-LopezMatthias SchreiberThomas KuntzeMahmoud Al JassemHarald LappPublished in: Journal of cardiovascular development and disease (2023)
Transcatheter aortic valve implantation (TAVI) is now a commonly used therapy in patients with severe aortic stenosis, even in those patients at low surgical risk. The indications for TAVI have broadened as the therapy has proven to be safe and effective. Most challenges associated with TAVI after its initial introduction have been impressively reduced; however, the possible need for post-TAVI permanent pacemaker implantation (PPI) secondary to conduction disturbances continues to be on the radar. Conduction abnormalities post-TAVI are always of concern given that the aortic valve lies in close proximity to critical components of the cardiac conduction system. This review will present a summary of noteworthy pre-and post-procedural conduction blocks, the best use of telemetry and ambulatory device monitoring to avoid unnecessary PPI or to recognize the need for late PPI due to delayed high-grade conduction blocks, predictors to identify those patients at greatest risk of requiring PPI, important CT measurements and considerations to optimize TAVI planning, and the utility of the MInimizing Depth According to the membranous Septum (MIDAS) technique and the cusp-overlap technique. It is stressed that careful membranous septal (MS) length measurement by MDCT during pre-TAVI planning is necessary to establish the optimal implantation depth before the procedure to reduce the risk of compression of the MS and consequent damage to the cardiac conduction system.
Keyphrases
- transcatheter aortic valve implantation
- aortic stenosis
- aortic valve
- ejection fraction
- aortic valve replacement
- transcatheter aortic valve replacement
- left ventricular
- protein protein
- high grade
- multiple sclerosis
- ms ms
- mass spectrometry
- coronary artery disease
- newly diagnosed
- small molecule
- early onset
- hypertrophic cardiomyopathy
- blood pressure
- oxidative stress
- cell therapy
- magnetic resonance